Evidence map›Paper›PMID 39613843›Full record

ArticleBritish journal of cancer2025

Tumor budding and lymphovascular invasion as prognostic factors in p16-positive oropharyngeal squamous cell carcinomas.

Fabian Stögbauer, Markus Wirth, Maren Lauterbach, Barbara Wollenberg, Benedikt Schmidl, Cosima C Hoch, Iordanis Ourailidis, Jochen Hess, Markus Eckstein, Arndt Hartmann and 15 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Fabian StögbauerTechnical University of Munich, TUM School of Medicine and Health, Institute of General and Surgical Pathology, Munich, Germany. fabian.stoegbauer@tum.de.ORCID http://orcid.org/0000-0002-8897-5165
Markus WirthDepartment of Otolaryngology, Head and Neck Surgery, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany.
Maren LauterbachDepartment of Otolaryngology, Head and Neck Surgery, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany.
Barbara WollenbergDepartment of Otolaryngology, Head and Neck Surgery, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany.
Benedikt SchmidlDepartment of Otolaryngology, Head and Neck Surgery, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany.
Cosima C HochDepartment of Otolaryngology, Head and Neck Surgery, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany.ORCID http://orcid.org/0000-0002-3875-7389
Iordanis OurailidisUniversity of Heidelberg, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.ORCID http://orcid.org/0000-0001-6783-5617
Jochen HessDepartment of Otorhinolaryngology, Head and Neck Surgery, Experimental Head and Neck Oncology, Heidelberg University Hospital, Heidelberg, Germany.ORCID http://orcid.org/0000-0003-3493-1711
Markus EcksteinInstitute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.ORCID http://orcid.org/0000-0001-5418-3349
Arndt HartmannInstitute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Heinrich IroBavarian Cancer Research Center (Bayerisches Zentrum für Krebsforschung, BZKF), Erlangen, Germany.
Antoniu-Oreste GostianBavarian Cancer Research Center (Bayerisches Zentrum für Krebsforschung, BZKF), Erlangen, Germany.
Matthias BalkBavarian Cancer Research Center (Bayerisches Zentrum für Krebsforschung, BZKF), Erlangen, Germany.
Moritz JesinghausInstitute of Pathology, University Hospital Marburg, Marburg, Germany.
Julika Ribbat-IdelInstitute of Pathology, University of Lübeck, Lübeck, Germany.
Verena-Wilbeth SailerPathology of the University Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.
Sven PernerCenter for Precision Oncology Tübingen, Tübingen, Germany.
Karl-Ludwig BruchhageDepartment of Otorhinolaryngology, University of Luebeck, Luebeck, Germany.
Markus HoffmannDepartment of Otorhinolaryngology, Head and Neck Surgery, Christian-Albrechts-University Kiel, Kiel, Germany.
Lukas LükewilleDepartment of Otorhinolaryngology, Head and Neck Surgery, Christian-Albrechts-University Kiel, Kiel, Germany.
Christiane Maria Stuhlmann-LaeiszDepartment for Pathology, Christian-Albrechts-University of Kiel, Kiel, Germany.
Christoph RöckenDepartment for Pathology, Christian-Albrechts-University of Kiel, Kiel, Germany.ORCID http://orcid.org/0000-0002-6989-8002
Carolin MoglerTechnical University of Munich, TUM School of Medicine and Health, Institute of General and Surgical Pathology, Munich, Germany.
Jan Budczies *University of Heidelberg, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-6668-5327
Melanie Boxberg *Technical University of Munich, TUM School of Medicine and Health, Institute of General and Surgical Pathology, Munich, Germany. melanie.boxberg@tum.de.ORCID http://orcid.org/0000-0001-5989-7922

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe aimed to validate the prognostic significance of tumor budding (TB) in p16-positive oropharyngeal squamous cell carcinomas (OPSCC).

methodsWe analyzed digitized H&E-stained slides from a multicenter cohort of five large university centers consisting of n = 275 cases of p16-positive OPSCC. We evaluated TB along with other histological parameters (morphology, tumor-stroma-ratio, lymphovascular invasion (LVI), perineural invasion) and calculated survival outcomes using both univariate and multivariate analyses.

resultsTB was identified as an independent prognostic parameter, with TB-high cases showing inferior outcomes in univariate (HR: 3.08, 95%-CI: 1.71-5.54) and multivariate analyses (HR: 4.03, 95%-CI: 1.65-9.83). Similarly, LVI remained an independent prognostic factor (HR: 3.00, 95%-CI: 1.22-7.38). A combined classification including TB and LVI stratified cases into low-, intermediate- and high-risk categories. We could not detect correlations between TB and the number of lymph node metastases or between TB and an extracapsular extension of lymph node metastases.

conclusionsIn addition to LVI, we could identify TB as an independent prognostic factor in p16-positive OPSCC in this multicenter study cohort. Thus, evaluating TB along with LVI in a combined scheme for prognostication might help to establish a more personalized treatment regimen for patients with p16-positive OPSCC.

Indexed as

Carcinoma, Squamous CellCyclin-Dependent Kinase Inhibitor p16Oropharyngeal NeoplasmsAdultAgedAged, 80 and overFemaleHumansLymphatic MetastasisMaleMiddle AgedNeoplasm InvasivenessPrognosisCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16

Identifiers

PMID39613843
PMCPMC11747400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.